期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

造血干细胞移植治疗多发性骨髓瘤的研究进展 被引量：3

Reviews of the Research on Hematopoietic Stem Cell Transplantation of Multiple Myeloma
下载PDF
导出
摘要 多发性骨髓瘤(MM)是浆细胞恶性克隆性疾病,造血干细胞移植治疗MM患者的疗效明显优于传统化疗,是初治MM患者的标准治疗方案。造血干细胞移植包括自体干细胞移值、异基因造血干细胞移植(包括清髓性异基因造血干细胞移植及非清髓异基因造血干细胞移植)。本文就造血干细胞移植治疗MM的疗效、预后因素、预处理方案、移植时机及二次移植等问题的研究进展进行了阐述。 Multiple myeloma is characterized by a neoplastic proliferation of a single clone of plasma cells engaged in the production of a momoclonal protein. This review will focus on the clinical therapeutic effect and prognostic factors of hematopoietic stem cell on Multiple Myeloma.
作者 刘红艳 夏凌辉 郭静明 王海燕 朱磊 刘斌
机构地区 三峡大学第一临床医院/宜昌市中心人民医院血液科 华中科技大学同济医学院附属协和医院血液科
出处 《武汉大学学报（医学版）》 CAS 2008年第2期275-278,共4页 Medical Journal of Wuhan University
关键词 多发性骨髓瘤 造血干细胞移植 Multiple Myeloma Hematopoietic Stem Cell Transplantation
分类号 R733.3 [医药卫生—肿瘤]
  • 相关文献

参考文献10

  • 1Fermand JP, Katsahian S, Divine M ,et al. High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the group myelome-autogreffe[J]. Clin Oncol, 2005, 23:9227-9233.
  • 2O'shea D,Giles C,Terpos E, et al. Predictive factors for survival in myeloma patients who undergo autologous stem cell transplantation., a single-centre experience in 211 patients [J]. Bone Marrow Transplant, 2006,27 : 335-341.
  • 3Tricot G. Prognostic factors in multiple myeloma[J]. Clin Adv Hematol Oncol, 2005,3 : 167-168.
  • 4Attal M, Harousseau JL, Facon T, et al, Double autologous transplantation improves survival of multiple myeloma patients: final analysis of a prospective randomised study of the “Intergroupe Francophone du Myelome” (IMF 94) [J]. Hematol J, 2003, 55:12-17.
  • 5Putkonen M,Rauhala A,hala M, et al. Double versus single autotransplantation in multiple myeloma; a single center experience of 100 patients[J]. Haematologica, 2005, 90:562-568.
  • 6Kroger N, Perez-Simon JA, Myint H, et al. Relapse to prior autograft and chronic graft-versus-host disease are the strongest prognostic factors for outcome of melphalan/fludarabine-based dose-reduced allogeneic stem cell transplantation in patients with multiple myelorna [J]. Biol Blood Marrow Transplant, 2004, 10: 698- 708.
  • 7Shimazaki C, Fujii H, Yoshida T, et al. Reduced-intensity conditioning allogeneic stem cell transplantation for multiple myeloma: results from the Japan myeloma study group[J]. Int J Hematol, 2005, 81: 342-348.
  • 8Gibson J, Ho PJ, Joshua D, et al. Evolving transplant options for multiple myeloma: Autologous and nonmyeloablative allogenic[J]. Transplantation Proceedings, 2004,36:2501-2503.
  • 9Badros A, Barlogie B, Siegel E, et al. Improved outcome of allogeneic transplantation in high-risk multiple myeloma patients after nonmyeloablative conditioning [J]. J Clin Oncol, 2002, 20:1295-1300.
  • 10Nakashima Y, Shiratsuchi M, Abe Y, et al. Sustained molecular remission by non-myeloablative stem cell transplantation after autologous hematopoietic stem cell transplantation in a patient with multiple myeloma[J]. Leuk Lymphoma, 2005,46:1217-1222.

同被引文献67

  • 1苗瑞新.造血干/祖细胞动员临床研究新进展[J].国际移植与血液净化杂志,2006,4(3):32-35. 被引量：2
  • 2张之南.血液病诊断及疗效标准[M].3版.北京:科学出版社,2008:1.
  • 3张晓辉（综述）,黄晓军（审校）.造血干细胞移植治疗多发性骨髓瘤的研究进展[J].国际输血及血液学杂志,2007,30(4):328-331. 被引量：2
  • 4Ashcroft AJ,Davies FE,Morgan GJ.Aetiology of bone disease and the role of bisphosphonates in multiple myeloma.Lancet Oncol,2003,4(5):284-292.
  • 5Dürr HR,Wegener B.KrdelA,et al.Multiple myeloma:surgery of the spine.Retrospective analysis of 27 patients.Spine,2002,27(3):320-324.
  • 6Adams J. The proteasome: a suitable antineoplastic target[J]. Nat Rev Cancer, 2004, 4(5): 349-360.
  • 7Hideshima T, Miltiades C, Akiyama M, et al. Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341[J]. Blood, 2003, 101(4): 1530-1534.
  • 8Roccaro AM, Hideshima T, Raje N, et al. Bortezomib mediates antiangi ogenesis in multiple myeloma via direct and indirect effects on endothelia1 cells[J]. Cancer Ras, 2006, 66(1): 184-191.
  • 9National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology Multiple Myeloma (V. 1. 2011). http: //www. nccn. org/peofessionals/physician_gle/PDF/myeloma. pdf.
  • 10Goldschmidt H, Lokhorst HM, Bertsch U, et al. Successful harvesting of peripheral hematopoietic stem cells after induction treatment with bort-ezomib, adriamycin, dexamethasone (PAD) in patients with newly diagnosed multiple myeloma(MM)[J]. Blood, 2008, 112: 3470.

引证文献3

二级引证文献13

武汉大学学报（医学版）
2008年 第2期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部